Related Experiment Video

Updated: Feb 7, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.8K

Mortality Among Patients With Chronic Hepatitis B Infection: The Chronic Hepatitis Cohort Study (CHeCS)

Danae Bixler1, Yuna Zhong1, Kathleen N Ly1

  • 1Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|July 31, 2018
PubMed

Insights

Chronic hepatitis B (CHB) patients die 14 years younger than the general population, facing higher mortality rates from all causes and liver disease. Official death certificates significantly underestimate CHB

Area of Science:

  • Hepatology
  • Public Health
  • Epidemiology

Background:

  • Hepatitis B virus (HBV) infection can lead to chronic hepatitis B (CHB).
  • Annual mortality data from death certificates may not fully capture the true burden of CHB-related deaths in the United States.

Purpose of the Study:

  • To compare mortality rates and age at death among CHB patients versus the general US population.
  • To assess the accuracy of death certificates in reporting CHB as a cause of death.

Main Methods:

  • Analysis of data from the Chronic Hepatitis Cohort Study (CHeCS) between 2006 and 2013.
  • Comparison of death rates and causes between CHB decedents and the US Multiple Cause of Death (MCOD) file.

Main Results:

  • CHB patients died at a mean age of 59.8 years, 14 years younger than the general population.
  • CHB patients exhibited significantly higher overall (RR=1.85) and liver-related mortality (RR=15.91).
  • Hepatitis B was underreported on death certificates for CHB decedents (19%) and those dying of liver disease (40%).

Conclusions:

  • CHB is associated with premature mortality and increased risk of death from all causes and liver disease.
  • Current death certificate data likely underestimate the mortality impact of CHB.
Abstract

Keywords:
cause of deathchronic hepatitis Bliver diseasemortalityrisk factors

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

23.9K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.0K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
Chronic Pharyngitis01:23

Chronic Pharyngitis

Chronic pharyngitis refers to persistent inflammation of the pharyngial mucosa.
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
12.2K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
592
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
310